SCHEMBL2721067

SCHEMBL2721067

COc1ccc(-c2onc(-c3ccccc3Cl)c2Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 4/20 0.44
ALDH1A1 P00352 3/20 0.44
NR1H4 Q96RI1 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HPGD P15428 1/20 0.44
PTGS2 P35354 2/20 0.44
PTGS1 P23219 1/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPSR1 Q6W5P4 2/20 0.42
TSHR P16473 2/20 0.42
S1PR1 P21453 1/20 0.42
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2723947 0.83 PTGS2 (0.59) GPBAR1MAPTLMNAALDH1A1NR1H4
SCHEMBL2720655 0.82 PTGS1 (0.43) GPBAR1SMN1; SMN2MAPTLMNAALDH1A1
SCHEMBL5730934 0.81 PTGS2 (0.54) SMN1; SMN2MAPTALDH1A1NR1H4MEN1
SCHEMBL4549984 0.81 PTGS2 (0.50) GPBAR1MAPTLMNAALDH1A1NR1H4
SCHEMBL9956787 0.80 HSP90AA1 (0.51) GPBAR1LMNAPTGS2PTGS1NPC1
SCHEMBL17845096 0.79 PTGS1 (0.60) GPBAR1SMN1; SMN2MAPTLMNAALDH1A1
SCHEMBL21780774 0.79 GPBAR1 (0.46) GPBAR1SMN1; SMN2MAPTLMNAALDH1A1
SCHEMBL2723070 0.78 TP53 (0.47) GPBAR1SMN1; SMN2MAPTLMNAALDH1A1
SCHEMBL17845087 0.77 TNK2 (0.39) SMN1; SMN2MAPTLMNAALDH1A1MEN1
SCHEMBL2721647 0.77 PTGS2 (0.45) GPBAR1SMN1; SMN2MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9540361-B2 N-substituted azetidine derivatives MERCK SHARP & DOHME B.V. (NL) 2017-01-10 US disclosed
EP-2655367-B1 N-SUBSTITUTED AZETIDINE DERIVATIVES MERCK SHARP & DOHME (NL) 2016-07-06 EP disclosed
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2016-05-12 US disclosed
EP-2655367-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES Merck Sharp & Dohme B.V. (NL) 2013-10-30 EP disclosed
WO-2012084711-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES MSD OSS B.V. (NL) 2012-06-28 WO disclosed
WO-2012052395-A1 ISOXAZOLE DERIVATIVES USED AS OESTROGEN MODULATORS N. V. ORGANON (NL) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160130262-A1 N-SUBSTITUTED AZETIDINE DERIVATIVES ESR2, ESR1, GPER1 GPBAR1 633/4885SMN1; SMN2 3941/4885MAPT 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.